Phil, a company focused on pharmaceutical commercialization, has secured $60 million in growth debt financing from K2 HealthVentures.
The company's PhilRx platform provides prescription services to pharmaceutical companies, patients and healthcare providers.
Providers can send a patient's prescription to PhilRx through the retail pharmacy section of their EMR. Phil then submits for prior authorization and works with the patient to schedule delivery of the medication, including free home delivery.
The company helps patients get their prescriptions covered by insurance by working with their providers to obtain the lowest out-of-pocket costs.
"In 2015, we set out to transform patient access – using software to break down barriers to novel, hard-to-obtain therapies. That bold idea has grown into a proven, scalable model that's reshaping care delivery," Deepak Thomas, founder and CEO of Phil, said in a statement.
"Today, AI marks a new inflection point – one that can reimagine patient care at unprecedented scale. With this financing, capital is no longer a constraint, and we have the freedom to continue redefining digital access. For me and the entire Phil team, the road ahead has never been more exciting – for our patients and all who share in our vision."
UK-based Plexāā, maker of the Bloom medical device for breast surgery, has closed a $4.5 million funding extension round.
Bloom is a wearable device to help breast cancer patients prepare for surgery and reconstruction. The device, which has a companion app, uses a technique called supraphysiological reconditioning, which involves thermally preconditioning the skin before an operation to help reduce complications during wound healing.
The company will use the funds to launch Bloom in the U.S. and accelerate innovation.
"I want to thank our team for the tremendous progress it has made to make this financing possible," Dr. Saahil Mehta, founder and CEO of Plexāā, said in a statement.
"The funds will support this pivotal launch and market expansion, as well as the exciting development of our technology platform – including devices and apps targeting additional surgical specialties and creating a whole new category in surgery."
